Suggestions
Kent Hawryluk
President & CEO at MBX Biosciences, Inc.
Kent Hawryluk is a seasoned entrepreneur with close to two decades of experience in establishing and expanding successful life sciences enterprises.
He currently holds the positions of co-founder, president, and CEO at MBX Biosciences, a prominent player in the industry.
His previous role was as a co-founder and chief business officer at Avidity Biosciences, a well-known publicly-traded genetic medicines company that garnered substantial equity financing and sealed a significant partnership with Eli Lilly under his leadership.
Kent's journey includes co-founding Marcadia Biotech and MB2, where he played a pivotal role in advancing unique peptide drugs for metabolic disorders to clinical proof-of-concept and eventual acquisitions by industry giants Roche and Novo Nordisk.
Since January 2003, Kent has contributed his expertise as a partner at Twilight Venture Partners, a venture capital fund focusing on seed- and early-stage life science startups.
His areas of expertise encompass launching and guiding companies, fostering corporate partnerships, overseeing mergers and acquisitions, devising sound business strategies, and serving on board directorships.
Kent pursued his education at esteemed institutions, earning an AB in Politics from Princeton University, an MBA from Northwestern University's Kellogg School of Management, and a Master of Science in Biology from Indiana University Indianapolis.
His professional journey includes leadership roles at various organizations such as MBX Biosciences, Twilight Venture Partners, Gemphire Therapuetics, MB2 LLC, Avidity Biosciences, Marcadia Biotech, JEGI Capital, Dow Jones, and The Prague Post.
Highlights
As CEO of MBX Biosciences, I am working with a team focused on helping people with rare endocrine disorders live fuller and healthier lives. Today on Rare Disease Day, I am happy to share my stripes and resources to help others learn about #hypoparathyroidism (HP), a rare disease affecting some 130,000 Americans. As Robert Noyce said, ”Knowledge is power. Knowledge shared is power multiplied.” By educating ourselves, and spreading the word, we can better support individuals and families navigating these challenges. To find out more visit the HypoPARAthyroidism Association’s website #RareDiseaseDay #HypoPARA
I am excited to announce that Rita Shah, PharmD today joins MBX Biosciences, Inc. in the new role of Vice President of Global Regulatory Affairs, overseeing the global regulatory process for all MBX programs. Rita brings 10 years of broad pharmaceutical experience in a multitude of therapeutic areas including respiratory, immunology, and gastroenterology both in rare and common diseases. Previously, she served as a Director of Regulatory Affairs at AstraZeneca and in various regulatory roles at Johnson & Johnson and Janssen. Rita, welcome to the MBX team!
